NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRINALIN is an oral extended-release combination tablet containing azatadine maleate (a first-generation antihistamine) and pseudoephedrine sulfate (a decongestant) approved in 1982. It is indicated for symptomatic relief of allergic rhinitis and nasal congestion. The combination works by blocking histamine receptors to reduce allergic symptoms while the decongestant reduces nasal swelling.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30); expect defensive strategy focused on brand loyalty and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRINALIN offers limited growth potential and few open positions (0 linked jobs), reflecting its late-lifecycle status. Career value derives from managing profitable legacy brands and defensive commercial strategy rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on TRINALIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.